Alpha Tau Reports Eight Glioblastoma Patients Alive in Trial
Alpha Tau Medical reported interim results from its REGAIN trial of Alpha DaRT, an implanted radiation therapy being studied for recurrent glioblastoma. All eight patients treated were alive at the November 11, 2026, data cutoff, and all six patients whose tumors had been assessed showed an objective response: five complete responses and one partial response. Median overall survival had not been reached, with median follow-up of 6.9 months among the six patients; the findings are preliminary given the small group and short follow-up. The planned treatment sources were implanted in all eight patients, with no unanticipated serious adverse events reported. Because REGAIN is an open-label, single-arm study primarily designed to assess feasibility and safety, the responses do not yet establish treatment efficacy; the company plans to continue enrollment toward 20 patients.




